Close Menu


The multi-cohort brain cancer study will include Kazia's investigational drug in a new arm, which will start enrolling patients in early 2021.

The company, which recently wrapped enrollment for a Phase II trial in China, is continuing to actively enroll patients in the US trial for the drug despite the COVID-19 pandemic.

The study failed to show Opdivo plus chemoradiation significantly improves PFS compared to standard of care in MGMT-methylated glioblastoma.